EGFR mutations and ALK fusions represent the most frequent targetable alterations with a prevalence of, respectively, 10–20% and 3–5% in a Caucasian population with lung adenocarcinomas (ADC) [3]. Here, ALK is linked to lung adenocarcinoma.